Clinical Trials Directory

Trials / Completed

CompletedNCT03451864

Maternal 25-hydroxy Vitamin D Level and Adverse Outcomes in Near Term and Full Term Neonates

Status
Completed
Phase
Study type
Observational
Enrollment
88 (actual)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Eighty-eight pregnant women and their newborns were enrolled in a cross-sectional study. Maternal serum 25-OHD was measured by ELISA

Detailed description

Eighty-eight pregnant women and their newborns were enrolled in a cross-sectional study. Maternal serum 25-OHD was measured by ELISA.Maternal 25 (OH) vitamin D measurement: Blood samples for determination of serum 25 (OH) vitamin D were collected by venipuncture and processed as follows: 3 mL blood were collected into plain tubes and allowed to clot for 30 minutes, then it was centrifuged at 1500 round per minute for 15 minutes at room temperature and the serum was separated into clean, properly labeled tubes and stored at ≤ -20°C till assay. Serum 25 (OH) vitamin D level was assessed by Enzyme-Linked ImmunoSorbent Assay (ELISA) using DRG 25-OH Vitamin D (total) ELISA (DRG International, Inc., USA) according to manufacturer's instructions. Vitamin D deficiency is defined by 25(OH) D levels less than 20 ng/d

Conditions

Interventions

TypeNameDescription
PROCEDUREVaginal deliveryclassic vaginal delivery
PROCEDURECesarean Sectionroutine lower segment cesarean scetion

Timeline

Start date
2016-09-01
Primary completion
2018-02-01
Completion
2018-02-24
First posted
2018-03-02
Last updated
2018-03-02

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03451864. Inclusion in this directory is not an endorsement.